Signal detection of Rhabdomyolysis and death for galantamine: a pharmacovigilance study

This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.

書誌詳細
第一著者: Karmaker, Swastika
その他の著者: Yasmin, Hasina
フォーマット: 学位論文
言語:English
出版事項: Brac University 2024
主題:
オンライン・アクセス:http://hdl.handle.net/10361/23271
id 10361-23271
record_format dspace
spelling 10361-232712024-06-09T21:03:52Z Signal detection of Rhabdomyolysis and death for galantamine: a pharmacovigilance study Karmaker, Swastika Yasmin, Hasina School of Pharmacy, Brac University Alzheimer’s disease Rhabdomyolysis Galantamine Dementia Alzheimer's disease Dementia Neuropharmacology This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. Cataloged from PDF version of thesis. Includes bibliographical references (pages 38-42). Galantamine is one of the common acetylcholinesterase inhibitors used to treat Alzheimer's disease, a neurodegenerative disorder. This study was conducted to determine the impact of galantamine on mortality rate and rhabdomyolysis using the FDA Event Reporting System(FAERS) database, which includes data from drug class and the whole database. Comparing the mortality rate of galantamine to that of other drugs and other class, it was found that 24 deaths were recorded on FAERS, compared to 456,120 and 680 deaths for other drugs and drug class, respectively. In this analysis, galantamine showed better mortality benefit than others. The ROR value of death cases for other drugs was 1.22(95%CI:0.81-1.83;p=0.3435) vs. drug class 0.31(95%CI:0.21-0.47;p<0.0001). Furthermore,8 rhabdomyolysis cases were recorded in FAERS, while 16379 and 19 cases were reported on other drugs and other class, respectively. It has been found that galantamine is more likely of causing rhabdomyolysis than other drugs. The Reporting Odds Ratio (ROR) value for rhabdomyolysis for other drugs was 11.35 (95%CI:5.65-22.80; p<0.0001) vs drug class 4.05(95%CI:1.77-9.29; p=0.0009). Swastika Karmaker B. Pharmacy 2024-06-09T09:21:02Z 2024-06-09T09:21:02Z ©2023 2023-02 Thesis ID 18346089 http://hdl.handle.net/10361/23271 en Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 54 pages application/pdf Brac University
institution Brac University
collection Institutional Repository
language English
topic Alzheimer’s disease
Rhabdomyolysis
Galantamine
Dementia
Alzheimer's disease
Dementia
Neuropharmacology
spellingShingle Alzheimer’s disease
Rhabdomyolysis
Galantamine
Dementia
Alzheimer's disease
Dementia
Neuropharmacology
Karmaker, Swastika
Signal detection of Rhabdomyolysis and death for galantamine: a pharmacovigilance study
description This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
author2 Yasmin, Hasina
author_facet Yasmin, Hasina
Karmaker, Swastika
format Thesis
author Karmaker, Swastika
author_sort Karmaker, Swastika
title Signal detection of Rhabdomyolysis and death for galantamine: a pharmacovigilance study
title_short Signal detection of Rhabdomyolysis and death for galantamine: a pharmacovigilance study
title_full Signal detection of Rhabdomyolysis and death for galantamine: a pharmacovigilance study
title_fullStr Signal detection of Rhabdomyolysis and death for galantamine: a pharmacovigilance study
title_full_unstemmed Signal detection of Rhabdomyolysis and death for galantamine: a pharmacovigilance study
title_sort signal detection of rhabdomyolysis and death for galantamine: a pharmacovigilance study
publisher Brac University
publishDate 2024
url http://hdl.handle.net/10361/23271
work_keys_str_mv AT karmakerswastika signaldetectionofrhabdomyolysisanddeathforgalantamineapharmacovigilancestudy
_version_ 1814308715000496128